Share Price and Basic Stock Data
Last Updated: December 18, 2025, 3:03 pm
| PEG Ratio | 95.25 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Biogen Pharmachem Industries Ltd operates in the finance and investments sector, with its share price recently standing at ₹0.72 and a market capitalization of ₹65.0 Cr. The company has shown a notable shift in revenue trends over the past few quarters. For instance, sales rose to ₹0.75 Cr in June 2023 after a period of stagnation, where previous quarters reported minimal or negative sales figures. This growth appears to signal a potential recovery, as sales further increased to ₹0.78 Cr by March 2024. However, the overall annual sales for FY 2025 are projected at ₹1.20 Cr, reflecting a decline from ₹2.38 Cr in FY 2024. This fluctuation raises questions about the company’s ability to maintain momentum in a competitive landscape where consistent revenue generation is critical for investor confidence.
Profitability and Efficiency Metrics
In terms of profitability, Biogen’s operating profit margin (OPM) stood at a remarkable 87.01% for FY 2025, highlighting the company’s efficiency in managing costs relative to its revenues. However, the reported figures also indicate a mixed performance in net profitability, with the company swinging from a loss of ₹1.59 Cr in June 2022 to a net profit of ₹1.21 Cr for the trailing twelve months. While the return on equity (ROE) at 0.39% suggests that the company is generating modest returns for its shareholders, the return on capital employed (ROCE) mirrors this sentiment, also at 0.39%. The substantial operating profit margin juxtaposed with the low net profitability raises concerns about sustainability, suggesting challenges in converting sales into actual profit.
Balance Sheet Strength and Financial Ratios
Biogen’s balance sheet presents a rather intriguing picture. The absence of borrowings, recorded at ₹0.00 Cr, indicates a conservative approach to debt, which should generally be seen as a strength. The company reported reserves of ₹8.82 Cr, a significant improvement from previous years when reserves were negative. This positive shift could reflect improved capital management and a more stable financial footing. However, the price-to-book value (P/BV) ratio stands at 0.68x, which may suggest that the stock is undervalued relative to its net assets, but it also raises questions about market confidence in the company’s growth prospects. Additionally, the current ratio of 29.65x implies an exceptional ability to cover short-term liabilities, yet such high liquidity could also indicate underutilization of capital.
Shareholding Pattern and Investor Confidence
The shareholding structure of Biogen Pharmachem is entirely public, with 100% of shares held by retail investors. This scenario has seen the number of shareholders increase from 1,90,531 in December 2022 to 2,93,327 by September 2025, reflecting growing interest and perhaps speculation around the stock. However, the lack of institutional investors—both foreign and domestic—might be a red flag for potential investors, as institutional backing often lends credibility and stability to a stock. The absence of promoter holdings also raises concerns about commitment and long-term vision from the company’s founding members, which can impact investor confidence moving forward.
Outlook, Risks, and Final Insight
Looking ahead, Biogen Pharmachem faces a mixed outlook. The recent uptick in sales and profitability metrics could signal a turnaround, but the volatility in revenue trends and the lack of institutional support pose significant risks. Investors might consider the company’s ability to sustain its current momentum while being wary of the inherent risks of a heavily retail-driven shareholder base. Moreover, while the financial stability indicated by zero borrowings and high liquidity is commendable, it could also lead to questions about growth strategies and capital deployment. For investors, understanding the balance between potential returns and the risks associated with market perception will be crucial in navigating Biogen’s future.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Modern Shares & Stockbrokers Ltd | 11.9 Cr. | 40.5 | 67.7/36.4 | 47.5 | 44.4 | 0.00 % | 3.32 % | 1.74 % | 10.0 |
| Monarch Networth Capital Ltd | 2,381 Cr. | 300 | 484/280 | 15.3 | 111 | 0.33 % | 33.3 % | 26.2 % | 10.0 |
| Monotype India Ltd | 33.0 Cr. | 0.47 | 2.02/0.45 | 4.58 | 0.03 | 0.00 % | 286 % | % | 1.00 |
| Multipurpose Trading & Agencies Ltd | 5.45 Cr. | 11.0 | 12.6/8.25 | 9.25 | 0.00 % | 3.68 % | 3.38 % | 10.0 | |
| Munoth Financial Services Ltd | 20.8 Cr. | 40.6 | 72.0/40.6 | 19.9 | 0.00 % | 2.41 % | 3.38 % | 10.0 | |
| Industry Average | 7,228.45 Cr | 1,373.88 | 82.41 | 3,844.37 | 0.36% | 21.71% | 14.20% | 7.22 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | -1.54 | -0.00 | -0.00 | -0.01 | 0.75 | -0.00 | -0.00 | 0.78 | -0.09 | -0.00 | 0.23 | 1.35 | 1.54 |
| Expenses | 0.05 | 0.11 | 0.03 | 0.19 | 0.34 | 0.04 | 0.03 | 0.04 | 0.07 | 0.35 | 0.54 | 0.17 | 0.20 |
| Operating Profit | -1.59 | -0.11 | -0.03 | -0.20 | 0.41 | -0.04 | -0.03 | 0.74 | -0.16 | -0.35 | -0.31 | 1.18 | 1.34 |
| OPM % | 54.67% | 94.87% | -134.78% | 87.41% | 87.01% | ||||||||
| Other Income | -0.00 | 2.05 | 0.33 | -0.00 | -0.00 | 0.76 | 0.09 | -0.00 | -0.00 | -0.65 | -0.00 | -0.00 | -0.00 |
| Interest | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Depreciation | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Profit before tax | -1.59 | 1.94 | 0.30 | -0.20 | 0.41 | 0.72 | 0.06 | 0.74 | -0.16 | -1.00 | -0.31 | 1.18 | 1.34 |
| Tax % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| Net Profit | -1.59 | 1.94 | 0.30 | -0.20 | 0.41 | 0.72 | 0.06 | 0.74 | -0.16 | -1.00 | -0.31 | 1.18 | 1.34 |
| EPS in Rs | -0.02 | 0.03 | 0.00 | -0.00 | 0.01 | 0.01 | 0.00 | 0.01 | -0.00 | -0.02 | -0.00 | 0.02 | 0.01 |
Last Updated: August 1, 2025, 6:10 am
Below is a detailed analysis of the quarterly data for Biogen Pharmachem Industries Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1.54 Cr.. The value appears strong and on an upward trend. It has increased from 1.35 Cr. (Mar 2025) to 1.54 Cr., marking an increase of 0.19 Cr..
- For Expenses, as of Jun 2025, the value is 0.20 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.17 Cr. (Mar 2025) to 0.20 Cr., marking an increase of 0.03 Cr..
- For Operating Profit, as of Jun 2025, the value is 1.34 Cr.. The value appears strong and on an upward trend. It has increased from 1.18 Cr. (Mar 2025) to 1.34 Cr., marking an increase of 0.16 Cr..
- For OPM %, as of Jun 2025, the value is 87.01%. The value appears to be declining and may need further review. It has decreased from 87.41% (Mar 2025) to 87.01%, marking a decrease of 0.40%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 1.34 Cr.. The value appears strong and on an upward trend. It has increased from 1.18 Cr. (Mar 2025) to 1.34 Cr., marking an increase of 0.16 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is 1.34 Cr.. The value appears strong and on an upward trend. It has increased from 1.18 Cr. (Mar 2025) to 1.34 Cr., marking an increase of 0.16 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.01. The value appears to be declining and may need further review. It has decreased from 0.02 (Mar 2025) to 0.01, marking a decrease of 0.01.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:03 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.11 | 0.95 | 0.00 | 1.62 | 2.47 | 0.00 | 2.38 | 1.20 | 1.58 |
| Expenses | 0.03 | 0.04 | 0.03 | 0.12 | 6.72 | 0.95 | 0.12 | 3.22 | 2.49 | 0.45 | 0.45 | 1.49 | 1.30 |
| Operating Profit | -0.03 | -0.04 | -0.03 | -0.12 | -6.61 | 0.00 | -0.12 | -1.60 | -0.02 | -0.45 | 1.93 | -0.29 | 0.28 |
| OPM % | -6,009.09% | 0.00% | -98.77% | -0.81% | 81.09% | -24.17% | 17.72% | ||||||
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.00 | 0.00 | 0.00 | 0.01 | 0.91 | 0.00 | 0.00 | 1.44 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.10 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.13 | -0.14 | -0.03 | -0.12 | -6.56 | 0.00 | -0.12 | -1.60 | -0.01 | 0.46 | 1.93 | -0.29 | 1.72 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||
| Net Profit | -0.13 | -0.13 | -0.03 | -0.12 | -6.56 | 0.00 | -0.12 | -1.60 | -0.01 | 0.46 | 1.93 | -0.29 | 1.72 |
| EPS in Rs | -0.00 | -0.00 | -0.00 | -0.00 | -0.10 | 0.00 | -0.00 | -0.02 | -0.00 | 0.01 | 0.03 | -0.00 | 0.02 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 76.92% | -300.00% | -5366.67% | 100.00% | -1233.33% | 99.38% | 4700.00% | 319.57% | -115.03% |
| Change in YoY Net Profit Growth (%) | 0.00% | 76.92% | -376.92% | -5066.67% | 5466.67% | -1333.33% | 1332.71% | 4600.62% | -4380.43% | -434.59% |
Biogen Pharmachem Industries Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -21% |
| TTM: | 352% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 30% |
| 3 Years: | -2% |
| 1 Year: | -34% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | 0% |
| 3 Years: | 1% |
| Last Year: | 0% |
Last Updated: September 5, 2025, 2:41 pm
Balance Sheet
Last Updated: December 4, 2025, 2:32 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 90.26 |
| Reserves | -4.14 | -4.27 | -4.30 | -4.42 | -10.98 | -10.99 | -9.51 | -11.12 | -11.13 | -10.67 | -8.74 | 26.67 | 8.82 |
| Borrowings | 57.21 | 10.00 | 6.21 | 0.72 | 0.01 | 0.63 | 0.31 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 4.93 | 2.49 | 1.64 | 1.69 | 1.64 | 2.73 | 0.03 | 0.11 | 0.82 | 0.24 | 0.30 | 0.09 | 0.10 |
| Total Liabilities | 123.26 | 73.48 | 68.81 | 63.25 | 55.93 | 57.63 | 56.09 | 54.25 | 54.95 | 54.83 | 56.82 | 92.02 | 99.18 |
| Fixed Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 60.86 | 43.78 | 26.69 | 22.39 | 3.52 | 6.25 | 6.45 | 9.49 | 6.95 | 8.85 | 5.44 | 23.84 | 21.37 |
| Other Assets | 62.40 | 29.70 | 42.12 | 40.86 | 52.41 | 51.38 | 49.64 | 44.76 | 48.00 | 45.98 | 51.38 | 68.18 | 77.81 |
| Total Assets | 123.26 | 73.48 | 68.81 | 63.25 | 55.93 | 57.63 | 56.09 | 54.25 | 54.95 | 54.83 | 56.82 | 92.02 | 99.18 |
Below is a detailed analysis of the balance sheet data for Biogen Pharmachem Industries Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 90.26 Cr.. The value appears strong and on an upward trend. It has increased from 65.26 Cr. (Mar 2025) to 90.26 Cr., marking an increase of 25.00 Cr..
- For Reserves, as of Sep 2025, the value is 8.82 Cr.. The value appears to be declining and may need further review. It has decreased from 26.67 Cr. (Mar 2025) to 8.82 Cr., marking a decrease of 17.85 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 0.10 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.09 Cr. (Mar 2025) to 0.10 Cr., marking an increase of 0.01 Cr..
- For Total Liabilities, as of Sep 2025, the value is 99.18 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 92.02 Cr. (Mar 2025) to 99.18 Cr., marking an increase of 7.16 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 21.37 Cr.. The value appears to be declining and may need further review. It has decreased from 23.84 Cr. (Mar 2025) to 21.37 Cr., marking a decrease of 2.47 Cr..
- For Other Assets, as of Sep 2025, the value is 77.81 Cr.. The value appears strong and on an upward trend. It has increased from 68.18 Cr. (Mar 2025) to 77.81 Cr., marking an increase of 9.63 Cr..
- For Total Assets, as of Sep 2025, the value is 99.18 Cr.. The value appears strong and on an upward trend. It has increased from 92.02 Cr. (Mar 2025) to 99.18 Cr., marking an increase of 7.16 Cr..
Notably, the Reserves (8.82 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -57.24 | -10.04 | -6.24 | -0.84 | -6.62 | -0.63 | -0.43 | -1.60 | -0.02 | -0.45 | 1.93 | -0.29 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 23,326.82 | 3,085.21 | 572.28 | 0.00 | 0.00 | 0.00 | ||||||
| Inventory Days | 0.00 | 0.00 | 0.00 | |||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 23,326.82 | 3,085.21 | 572.28 | 0.00 | 0.00 | 0.00 | ||||||
| Working Capital Days | 23,194.09 | 2,651.05 | 549.75 | 152.21 | -35.27 | 170.33 | ||||||
| ROCE % | -0.14% | -0.15% | -0.04% | -0.19% | -11.32% | 0.00% | -0.22% | -2.90% | -0.02% | -0.37% | 3.47% | -0.39% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 0.00 | 0.03 | 0.01 | 0.00 | -0.02 |
| Diluted EPS (Rs.) | 0.00 | 0.03 | 0.01 | 0.00 | -0.02 |
| Cash EPS (Rs.) | 0.00 | 0.02 | 0.01 | 0.00 | -0.02 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 1.41 | 0.86 | 0.83 | 0.82 | 0.82 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 1.41 | 0.86 | 0.83 | 0.82 | 0.82 |
| Revenue From Operations / Share (Rs.) | 0.00 | 0.00 | 0.00 | 0.03 | 0.02 |
| PBDIT / Share (Rs.) | 0.00 | 0.02 | 0.01 | 0.00 | -0.02 |
| PBIT / Share (Rs.) | 0.00 | 0.02 | 0.01 | 0.00 | -0.02 |
| PBT / Share (Rs.) | 0.00 | 0.02 | 0.01 | 0.00 | -0.02 |
| Net Profit / Share (Rs.) | 0.00 | 0.02 | 0.01 | 0.00 | -0.02 |
| PBDIT Margin (%) | 0.00 | 0.00 | 0.00 | -0.34 | -98.80 |
| PBIT Margin (%) | 0.00 | 0.00 | 0.00 | -0.34 | -98.80 |
| PBT Margin (%) | 0.00 | 0.00 | 0.00 | -0.34 | -98.80 |
| Net Profit Margin (%) | 0.00 | 0.00 | 0.00 | -0.34 | -98.80 |
| Return on Networth / Equity (%) | -0.31 | 3.41 | 0.83 | -0.01 | -2.96 |
| Return on Capital Employeed (%) | -0.31 | 3.41 | 0.83 | -0.01 | -2.96 |
| Return On Assets (%) | -0.31 | 3.39 | 0.83 | -0.01 | -2.95 |
| Asset Turnover Ratio (%) | 0.00 | 0.00 | 0.00 | 0.04 | 0.02 |
| Current Ratio (X) | 29.65 | 0.30 | 0.64 | 2.37 | 23.64 |
| Quick Ratio (X) | 29.65 | 0.30 | 0.64 | 2.37 | 23.64 |
| Interest Coverage Ratio (X) | 0.00 | 0.00 | 0.00 | -46.77 | -34255.66 |
| Interest Coverage Ratio (Post Tax) (X) | 0.00 | 0.00 | 0.00 | -46.77 | -34255.66 |
| Enterprise Value (Cr.) | 60.63 | 69.16 | 38.37 | 91.28 | 13.70 |
| EV / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 36.89 | 8.44 |
| EV / EBITDA (X) | -207.15 | 35.82 | 84.25 | -10849.12 | -8.54 |
| MarketCap / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 36.93 | 8.45 |
| Price / BV (X) | 0.68 | 1.22 | 0.70 | 1.69 | 0.25 |
| Price / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 36.94 | 8.47 |
| EarningsYield | 0.00 | 0.02 | 0.01 | 0.00 | -0.11 |
After reviewing the key financial ratios for Biogen Pharmachem Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.00, marking a decrease of 0.03.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.00, marking a decrease of 0.03.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.41. It has increased from 0.86 (Mar 24) to 1.41, marking an increase of 0.55.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.41. It has increased from 0.86 (Mar 24) to 1.41, marking an increase of 0.55.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 2. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 2. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For PBDIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Net Profit Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Return on Networth / Equity (%), as of Mar 25, the value is -0.31. This value is below the healthy minimum of 15. It has decreased from 3.41 (Mar 24) to -0.31, marking a decrease of 3.72.
- For Return on Capital Employeed (%), as of Mar 25, the value is -0.31. This value is below the healthy minimum of 10. It has decreased from 3.41 (Mar 24) to -0.31, marking a decrease of 3.72.
- For Return On Assets (%), as of Mar 25, the value is -0.31. This value is below the healthy minimum of 5. It has decreased from 3.39 (Mar 24) to -0.31, marking a decrease of 3.70.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Current Ratio (X), as of Mar 25, the value is 29.65. This value exceeds the healthy maximum of 3. It has increased from 0.30 (Mar 24) to 29.65, marking an increase of 29.35.
- For Quick Ratio (X), as of Mar 25, the value is 29.65. This value exceeds the healthy maximum of 2. It has increased from 0.30 (Mar 24) to 29.65, marking an increase of 29.35.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Enterprise Value (Cr.), as of Mar 25, the value is 60.63. It has decreased from 69.16 (Mar 24) to 60.63, marking a decrease of 8.53.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EV / EBITDA (X), as of Mar 25, the value is -207.15. This value is below the healthy minimum of 5. It has decreased from 35.82 (Mar 24) to -207.15, marking a decrease of 242.97.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 1. It has decreased from 1.22 (Mar 24) to 0.68, marking a decrease of 0.54.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Biogen Pharmachem Industries Ltd:
- Net Profit Margin: 0%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -0.31% (Industry Average ROCE: 21.71%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -0.31% (Industry Average ROE: 14.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 29.65
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 37.8 (Industry average Stock P/E: 82.41)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Finance & Investments | Shop No. 8, First Floor, Makers - 1 Building, Rajkot Gujarat 360001 | suntechnooverseas@gmail.com http://www.biogenpharma.life |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Kelash Bunkar | WholeTime Director & CFO |
| Mr. Chandrakant Govindbhai Parmar | Director |
| Mr. Chhayaben Parmar | Director |
| Mr. Narendrakumar Vaniya | Director |
| Mr. Aman Patel | Director |
| Mr. Harshadkumar Rathod | Director |
FAQ
What is the intrinsic value of Biogen Pharmachem Industries Ltd?
Biogen Pharmachem Industries Ltd's intrinsic value (as of 18 December 2025) is 0.13 which is 81.94% lower the current market price of 0.72, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 65.0 Cr. market cap, FY2025-2026 high/low of 1.23/0.71, reserves of ₹8.82 Cr, and liabilities of 99.18 Cr.
What is the Market Cap of Biogen Pharmachem Industries Ltd?
The Market Cap of Biogen Pharmachem Industries Ltd is 65.0 Cr..
What is the current Stock Price of Biogen Pharmachem Industries Ltd as on 18 December 2025?
The current stock price of Biogen Pharmachem Industries Ltd as on 18 December 2025 is 0.72.
What is the High / Low of Biogen Pharmachem Industries Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Biogen Pharmachem Industries Ltd stocks is 1.23/0.71.
What is the Stock P/E of Biogen Pharmachem Industries Ltd?
The Stock P/E of Biogen Pharmachem Industries Ltd is 37.8.
What is the Book Value of Biogen Pharmachem Industries Ltd?
The Book Value of Biogen Pharmachem Industries Ltd is 1.10.
What is the Dividend Yield of Biogen Pharmachem Industries Ltd?
The Dividend Yield of Biogen Pharmachem Industries Ltd is 0.00 %.
What is the ROCE of Biogen Pharmachem Industries Ltd?
The ROCE of Biogen Pharmachem Industries Ltd is 0.39 %.
What is the ROE of Biogen Pharmachem Industries Ltd?
The ROE of Biogen Pharmachem Industries Ltd is 0.39 %.
What is the Face Value of Biogen Pharmachem Industries Ltd?
The Face Value of Biogen Pharmachem Industries Ltd is 1.00.